FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1966741541> ?p ?o ?g. }

• W1966741541 endingPage "141" @default.
• W1966741541 startingPage "135" @default.
• W1966741541 abstract "A 3-year prospective, randomized, placebo-controlled trial of oral clodronate 800 mg showed that the incidence of clinical fractures was decreased by 20% in 5596 elderly women unselected for osteoporosis. The effect occurred in the absence of systematic calcium and vitamin D supplementation and was observed across a wide range of BMDs. Introduction: To date, most studies with bisphosphonates have reported on their use in individuals selected to be at high risk for fracture usually by the presence of low BMD or a prior fragility fracture, usually of the spine. We wished to determine the effect of the bisphosphonate, clodronate, on the rate of fractures in women ⩾75 years of age living in the community. Materials and Methods: Women ⩾75 years of age living in the general community in South Yorkshire and North Derbyshire, identified from general practice registers, were recruited by letter of invitation to a randomized, double-blind, controlled trial of 800 mg oral clodronate (Bonefos) or matching placebo daily over 3 years. The main outcomes were the incidences of hip and any clinical fracture. Results: Of the 5579 elderly women included in the intention-to-treat analysis of efficacy, 114 had a new hip fracture during the 3-year treatment phase: 56 (2.0%) women in the clodronate group and 58 (2.1%) women in the placebo group (hazard ration [HR], 1.02; 95% CI, 0.71–1.47). Clodronate did, however, decrease the incidence of any clinical fracture by 20% (264 women [9.5%] versus 337 [12.1%] in the placebo group; HR, 0.80; 95% CI, 0.68–0.94). The incidence of osteoporosis-associated nonhip fractures was also significantly decreased by 29% (5.2% versus 7.4%; HR, 0.71; 95% CI, 0.57–0.87). The ability of clodronate to reduce the risk of osteoporotic fracture was independent of baseline BMD, but the number needed-to-treat was lower in the presence of osteoporosis. Conclusions: Oral daily clodronate can prevent fractures without significant adverse effects in elderly women living in the general community. The effect on hip fracture risk is not significant, but an effect similar to that at other nonvertebral sites cannot be excluded. This study suggests that antiresorptive therapies can reduce fracture incidence in high-risk individuals even in the presence of a normal or osteopenic BMD." @default.
• W1966741541 created "2016-06-24" @default.
• W1966741541 creator A5003808891 @default.
• W1966741541 creator A5007276743 @default.
• W1966741541 creator A5011673886 @default.
• W1966741541 creator A5022859538 @default.
• W1966741541 creator A5024756058 @default.
• W1966741541 creator A5030903262 @default.
• W1966741541 creator A5037004738 @default.
• W1966741541 creator A5038506845 @default.
• W1966741541 creator A5039316775 @default.
• W1966741541 creator A5046738851 @default.
• W1966741541 creator A5076192893 @default.
• W1966741541 creator A5079097690 @default.
• W1966741541 creator A5080195917 @default.
• W1966741541 creator A5083105018 @default.
• W1966741541 creator A5084045220 @default.
• W1966741541 creator A5087414266 @default.
• W1966741541 date "2006-10-16" @default.
• W1966741541 modified "2023-10-10" @default.
• W1966741541 title "Clodronate Reduces the Incidence of Fractures in Community-Dwelling Elderly Women Unselected for Osteoporosis: Results of a Double-Blind, Placebo-Controlled Randomized Study" @default.
• W1966741541 cites W1505358055 @default.
• W1966741541 cites W1593442063 @default.
• W1966741541 cites W1967591628 @default.
• W1966741541 cites W1986621723 @default.
• W1966741541 cites W2021895727 @default.
• W1966741541 cites W2047219483 @default.
• W1966741541 cites W2051581149 @default.
• W1966741541 cites W2064737447 @default.
• W1966741541 cites W2071508609 @default.
• W1966741541 cites W2082233939 @default.
• W1966741541 cites W2096150705 @default.
• W1966741541 cites W2102123887 @default.
• W1966741541 cites W2112629831 @default.
• W1966741541 cites W2122398315 @default.
• W1966741541 cites W2122802647 @default.
• W1966741541 cites W2124527463 @default.
• W1966741541 cites W2126253382 @default.
• W1966741541 cites W2153009489 @default.
• W1966741541 cites W2156015681 @default.
• W1966741541 cites W2161837912 @default.
• W1966741541 cites W2314892802 @default.
• W1966741541 doi "https://doi.org/10.1359/jbmr.061008" @default.
• W1966741541 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17042717" @default.
• W1966741541 hasPublicationYear "2006" @default.
• W1966741541 type Work @default.
• W1966741541 sameAs 1966741541 @default.
• W1966741541 citedByCount "176" @default.
• W1966741541 countsByYear W19667415412012 @default.
• W1966741541 countsByYear W19667415412013 @default.
• W1966741541 countsByYear W19667415412014 @default.
• W1966741541 countsByYear W19667415412015 @default.
• W1966741541 countsByYear W19667415412016 @default.
• W1966741541 countsByYear W19667415412017 @default.
• W1966741541 countsByYear W19667415412018 @default.
• W1966741541 countsByYear W19667415412019 @default.
• W1966741541 countsByYear W19667415412020 @default.
• W1966741541 countsByYear W19667415412021 @default.
• W1966741541 countsByYear W19667415412022 @default.
• W1966741541 countsByYear W19667415412023 @default.
• W1966741541 crossrefType "journal-article" @default.
• W1966741541 hasAuthorship W1966741541A5003808891 @default.
• W1966741541 hasAuthorship W1966741541A5007276743 @default.
• W1966741541 hasAuthorship W1966741541A5011673886 @default.
• W1966741541 hasAuthorship W1966741541A5022859538 @default.
• W1966741541 hasAuthorship W1966741541A5024756058 @default.
• W1966741541 hasAuthorship W1966741541A5030903262 @default.
• W1966741541 hasAuthorship W1966741541A5037004738 @default.
• W1966741541 hasAuthorship W1966741541A5038506845 @default.
• W1966741541 hasAuthorship W1966741541A5039316775 @default.
• W1966741541 hasAuthorship W1966741541A5046738851 @default.
• W1966741541 hasAuthorship W1966741541A5076192893 @default.
• W1966741541 hasAuthorship W1966741541A5079097690 @default.
• W1966741541 hasAuthorship W1966741541A5080195917 @default.
• W1966741541 hasAuthorship W1966741541A5083105018 @default.
• W1966741541 hasAuthorship W1966741541A5084045220 @default.
• W1966741541 hasAuthorship W1966741541A5087414266 @default.
• W1966741541 hasBestOaLocation W19667415411 @default.
• W1966741541 hasConcept C120665830 @default.
• W1966741541 hasConcept C121332964 @default.
• W1966741541 hasConcept C124490489 @default.
• W1966741541 hasConcept C126322002 @default.
• W1966741541 hasConcept C141071460 @default.
• W1966741541 hasConcept C142724271 @default.
• W1966741541 hasConcept C168563851 @default.
• W1966741541 hasConcept C1862650 @default.
• W1966741541 hasConcept C204787440 @default.
• W1966741541 hasConcept C207103383 @default.
• W1966741541 hasConcept C27081682 @default.
• W1966741541 hasConcept C2776541429 @default.
• W1966741541 hasConcept C2777251235 @default.
• W1966741541 hasConcept C2778885795 @default.
• W1966741541 hasConcept C44249647 @default.
• W1966741541 hasConcept C535046627 @default.
• W1966741541 hasConcept C61511704 @default.
• W1966741541 hasConcept C71924100 @default.
• W1966741541 hasConceptScore W1966741541C120665830 @default.
• W1966741541 hasConceptScore W1966741541C121332964 @default.

• next